Periodate-triggered cross-linking reveals Sug2/Rpt4 as the molecular target of a peptoid inhibitor of the 19S proteasome regulatory particle

Division of Translational Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9185, USA.
Journal of the American Chemical Society (Impact Factor: 11.44). 11/2007; 129(43):12936-7. DOI: 10.1021/ja075469+
Source: PubMed

ABSTRACT This study describes the identification of the protein target of the first chemical inhibitor (RIP-1) of t he 19S regulatory particle (RP) of the 25S proteasome. Periodate-triggered chemical cross-linking of DOPA-conjugate RIP-1 and the 26S proteasome identified Sug2/Rpt4, one of the six ATPases in the 19S as the molecular target of RIP-1 for Sug2/Rpt4 was domonstarated by examining cross-linking reactions with each ATPase if tge 19S RP. RIP-1 should provide a useful biological tool to probe the various biological roles of Sug2/Rpt4.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as a first-line therapy in combination with an alkylating agent and a corticosteroid. Furthermore, bortezomib has also been approved as a second-line therapy for mantle cell lymphoma. In this chapter, the focus is on the current clinical research on bortezomib, its adverse effects, and the resistance of multiple myeloma patients to bortezomib-based therapy. The various applications of bortezomib in different diseases and recent advances in the development of a new generation of inhibitors that target the proteasome or other parts of the ubiquitin-proteasome system are also reviewed.
    Progress in molecular biology and translational science 01/2012; 109:161-226. DOI:10.1016/B978-0-12-397863-9.00005-5 · 3.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ubiquitin-proteasomal system is an essential element of the protein quality control machinery in cells. The central part of this system is the 20S proteasome. The proteasome is a barrel-shaped multienzyme complex, containing several active centers hidden at the inner surface of the hollow cylinder. So, the regulation of the substrate entry toward the inner proteasomal surface is a key control mechanism of the activity of this protease. This chapter outlines the knowledge on the structure of the subunits of the 20S proteasome, the binding and structure of some proteasomal regulators and inducible proteasomal subunits. Therefore, this chapter imparts the knowledge on proteasomal structure which is required for the understanding of the following chapters.
    Progress in molecular biology and translational science 01/2012; 109:1-39. DOI:10.1016/B978-0-12-397863-9.00001-8 · 3.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Phenotype-based screening has been recognized as an important research tool for the discovery of novel therapeutic agents. However, the subsequent identification (ID) of the target of bioactive small molecules has been a major bottleneck in the general application of phenotype-based screening to the drug discovery process. The outcome of conventional target ID methods is significantly influenced by the inherent binding affinity of bioactive small molecules, which can be easily affected by experimental buffer conditions and nonspecific interactions. To overcome these limitations in affinity-based target ID, there has been a community effort to develop new target ID methods. In this review, we focus on the paradigm shift in target ID from noncovalent to covalent bonds and the associated issues in target identification.
    Molecular BioSystems 01/2013; DOI:10.1039/c2mb25502b · 3.35 Impact Factor


Available from